Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On ...

By Mariam Sunny March 23 (Reuters) - Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines ...

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new meaning to its partner Galapagos. By acquiring GSK-founded Ouro Medicines, ...

OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course. Gamgertamig has been granted both fast track and orphan drug designation ...

Gilead increased CEO Daniel O’Day's compensation by 20% in 2025 to $28.4 million, putting him among the highest-paid chief ...

Gilead Sciences Inc. is in advanced talks to acquire Ouro Medicines, a closely held company testing novel antibody drugs ...

Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.

Gilead Sciences has built up its position in the hot area of T-cell engagers (TCEs) for autoimmune diseases with an agreement ...

Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro MedicinesNew partnership structure ...

California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years ...